All In Biotech

Drug Trial Radar · NCT03335371

Evaluation of TTP399 in Patients With Type 1 Diabetes

A Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose, Adaptive Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of TTP399 in With Adult Patients Type 1 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Jul 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 115 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

115

Actual

Start

Oct 25, 2017

Primary completion

Dec 20, 2019

Study completion Jan 6, 2020

Sponsor

Lead sponsor
vTv TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Juvenile Diabetes Research Foundation
First posted
Nov 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of TTP399 in Type 1 diabetics. This study will be in 2 phases: phase 1 will evaluate the safety of different TTP399 dosage regimens over 1 week of daily dosing. Phase 2 will evaluate the safety and efficacy of a TTP399 dosing regimen over 12 weeks of daily dosing.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

  • TTP399Drug

    Phase 1: Participants will receive TTP399 administered orally up to 1200 mg taken once daily for 7 days

  • TTP399Drug

    Phase 2: Participants will receive TTP399 administered orally 800 mg taken once daily for 12 weeks

  • Placebo Oral TabletDrug

    Phase 2: Participants will receive Placebo oral tablets for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12Time frame: Baseline (Day 1) to Week 13
  2. Sentinel - Area Under the Concentration Time Curve (AUC)Time frame: Predose, 60, 90, 120, 150, 180, 240, 360 (6hr) and 540min (9hr) after dosing.
  3. Sentinel - Maximum Drug Concentration (Cmax)Time frame: Predose, 60, 90, 120, 150, 180, 240, 360 (6hr) and 540min (9hr) after dosing.
  4. Sentinel - Time to Maximum Concentration (Tmax)Time frame: Predose, 60, 90, 120, 150, 180, 240, 360 (6hr) and 540min (9hr) after dosing.

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • USC Westside Center for Diabetes

    Beverly Hills, California

  • AMCR Institute

    Escondido, California

  • University of Colorado Barbara Davis Center

    Aurora, Colorado

  • Atlanta Diabetes Associate

    Atlanta, Georgia

  • Rocky Mountain Diabetes Center

    Idaho Falls, Idaho

  • Iowa Diabetes Research

    West Des Moines, Iowa

  • Mountain Diabetes and Endocrine Center

    Asheville, North Carolina

  • UNC Diabetes Care Center

    Chapel Hill, North Carolina

  • Duke University Diabetes Research Clinic

    Durham, North Carolina

  • Diabetes & Endocrinology Consultants

    Morehead City, North Carolina

  • PMG Research of Wilmington

    Wilmington, North Carolina

  • Wake Forest

    Winston-Salem, North Carolina

  • Intend Research

    Norman, Oklahoma

  • Dallas Diabetes Research Center

    Dallas, Texas

  • University of Washington Medicine Diabetes Institute

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.